|
Orthologous residues
|
|
Bim (human): S59‑p, Bim iso2 (human): ‑, Bim iso3 (human): ‑, Bim (mouse): S55‑p, Bim (rat): S55‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
FL5.12 (lymphoid) [Bim (mouse)]
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ERK1 (mouse)
|
pharmacological inhibitor of upstream enzyme
|
|
|
KINASE
|
ERK2 (mouse)
|
pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
IL-3
|
|
|
|
increase
|
|
|
U0126
|
IL-3
|
|
|
inhibit treatment-induced increase
|
|
|
PD98059
|
IL-3
|
|
|
inhibit treatment-induced increase
|
|
|
LY294002
|
IL-3
|
|
|
no effect upon treatment-induced increase
|
|
|
SP600125
|
IL-3
|
|
|
no effect upon treatment-induced increase
|
|
|
SB203580
|
IL-3
|
|
|
no effect upon treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
apoptosis, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
Bax (mouse)
|
|
Disrupts
|
|
apoptosis, altered
|
co-immunoprecipitation
|
|